Cite
HARVARD Citation
Zeidner, J. et al. (2018). Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML). Leukemia research. pp. 92-95. [Online].